NCT Number,Study Title,Study URL,Study Status,Conditions,Interventions,Primary Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT05178901,A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects,https://clinicaltrials.gov/study/NCT05178901,COMPLETED,Nipah Virus Infection,BIOLOGICAL: PHV02|OTHER: Placebo,"Number of participants with treatment-related adverse events as assessed by the Toxicity Grading Scale, for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials, 42 days after vaccination|Number of participants with Nipah-specific antibody and neutralizing antibody responses as assessed by ELISA, for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials, 29 days after vaccination",Public Health Vaccines LLC,Coalition for Epidemic Preparedness Innovations,ALL,ADULT,PHASE1,60,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",PHV02-C-101,2022-01-10,2023-05-30,2023-05-30,2022-01-05,,2024-10-24,"Johnson County Clin-Trials(JCCT), Lenexa, Kansas, 66219, United States",
